Get started

ZOM

ZOM to retest the 200ma perhaps?I think the latest days have been amazing for ZOM, Truforma is coming in Q121 and so other solutions in the pipeline, the prospects for the company are very good. This team have been working for years and deserve a better company stock valuation now with their new developed technology. For the short time, I think the stock is likely to retest the 200ma, perhaps around 12ish and consolidate, but I wouldn't get surprise if the stock shoots up to 20 cents or over.
AMEX:ZOMLong
by Allenvik
Important week At this moment it is really hard to tell what to expect on monday or this week. 2 scenarios:ZOM is moving high, breaking $0.17 resistance and move above $0.20 and stay at that level for at least 10 days ,if it fail to get above $0.20 it will be delisted=price will drop (possibly lower than $0.07) .But I am sure monday will be interesting trading day, most-likely we will see a move towards $0.15 area, but I can be wrong again ;) . I am still holding my bag and also added more shares to it at 30% "discount" .Risky? -YES!
AMEX:ZOM
by RotanimreT
3
High chance of reverse split .To early to tell, but I think there is a good chance that ZOM shifted from distribution phase in to accumulation phase .$0.12 price level is showing strong support and it is also (in my opinion ) psychological point -moving past that level can potentially trigger an avalanche .At this moment we can expect price to move sometime in $0.12-$.13 channel . Reverse split might have a positive impact on the price of ZOM ,penny stocks have a bad reputation, and that's not what most legitimate companies want to have. So a reverse split can boost the stock to a “respectable” price. This may lead to increased attention from analysts and investors, who may see the company as more legitimate at the higher price, many institutional investors and mutual funds have policies against taking positions in a stock whose price is below a minimum value. August 27, 2020 Dear Zomedica Shareholders: As I pass my second month anniversary at Zomedica, I have been looking forward to communicating with you directly and to offering both my impressions of the Company and an update on our progress. I am pleased to report that I have been impressed by what I have seen since assuming the CEO role. I believe that the core technology, planned products, and employee base of Zomedica are strong, and that our future is bright. Recognizing that the Company has been through some challenging times in the recent past, we now all are united in the singular goal of advancing our lead product platform -- TRUFORMA™ -- to market as expeditiously as possible without sacrificing the quality of the product, which is critically important to Zomedica. Our intent is to launch TRUFORMA with five assays, which I believe immediately will make it a valuable contributor to the veterinarian's practice, both clinically and economically. This means that we are, in effect, developing five products simultaneously, which is a substantial undertaking. As reported in past news releases, in partnership with a subsidiary of Qorvo, Inc., which had revenues last year of over US $3.0 billion, we already successfully have verified three of the assays, and work is progressing on the remaining two. Proper testing is an important part of any product development effort, but more so when your product will be used to diagnose a living animal. We never forget this responsibility and we do not compromise in this area. That is why product development takes longer than some people would like. Validation must follow verification, and then market testing occurs prior to commercial release. While we have worked to streamline this process, it still takes time. We certainly appreciate, and hope to reward, your patience in the not-too-distant future. As I write this letter, we have more than US $50 million in cash and cash equivalents as a result of our capital raising activities in 2020. By taking advantage of favorable market conditions, we believe that we now have sufficient cash to take us well beyond TRUFORMA commercialization and have reduced dramatically the financing risk that previously has been an issue for our company. This additional capital also puts Zomedica in a better position to weather any new adverse consequences of the pandemic. We intend to be good stewards of our capital and will continue to embrace a "lean and mean" operating philosophy. Our commercial team has been working hard to prepare for the upcoming market release of TRUFORMA. We intend to pursue a hybrid sales model for the United States utilizing a small number of high-quality regional distributors who will be supported in the field by our own Zomedica direct sales employees, some of whom will service key geographies independently of our distributors. We also plan to have several veterinary clinical direct employees who, when needed, can provide deep clinical expertise on our products and their applications. Our goal is to assemble a selling organization that is appropriate for a variety of circumstances and to be ready to hit the ground running with a sizeable effort and preexisting customer relationships from day one. The behind-the-scenes effort employed to develop marketing and educational materials also is in full swing. The sales organization that we are building is intended not only to support TRUFORMA, our customers and their patients, but also to be suitable for future Zomedica products. I am looking forward to our Annual Meeting of Shareholders. Normally, I look forward to meeting as many shareholders as I can in person, but these are unusual times. I hope to address most, if not all, of your questions at the virtual meeting. While I realize that we have a "crowded" proxy statement, one agenda item for the meeting that I know is the subject of discussion among shareholders is the proposed reverse split, or consolidation, of our outstanding common shares. We are seeking your approval for the reverse split in order to comply with a specific requirement of the NYSE American exchange that we increase the trading price of our common shares. If we do not receive shareholder approval for the reverse split at the Annual Meeting, our common shares will be delisted from the NYSE American. It is important for us to maintain our listing to assure that there is a liquid market for our common shares. The reverse split is intended only to increase our stock price by reducing the number of shares outstanding, which is a purely mathematical exercise that does not affect your ownership interest in the Company . Accordingly, our Board of Directors has recommended that shareholders vote in favor of the reverse split. Finally, I would like to wish you all well during this difficult time. We at Zomedica have adjusted to the new COVID environment, with the majority of us working remotely. We proactively are addressing COVID-related issues that could impact our commercial launch, including by the development and implementation of remote installation capability for our TRUFORMA instrument. In summary, I believe that we now are well capitalized and well equipped to face the challenges ahead of us as we move toward commercialization. These are exciting times. Stay safe and healthy, and I look forward to delivering additional updates as we make further progress with our key milestones. Robert Cohen
AMEX:ZOMLong
by RotanimreT
Call it wishful thinking.I am holding relatively large bag and my vision can be distorted because of that fact .But here is my price prediction (target) for the next 10 days or so.I am not discounting possibility of ZOM moving down to $0.13 area right before it move up towards $0.27-$0.34 area ,possibly as high as $0.39. My original target was at $0.22 , but after doing some thinking and reading I have decided to move it higher (white horizontal line )If I am wrong then I will switch to plan B.Thanks for your time.
AMEX:ZOMLong
by RotanimreT
5
ZOM - Zomedica Pharmaceuticals Corp Technical AnalysisTechnical Analysis - Based on the last month price behaviour that after the Public offering the share from 0.15 went up to more than 0.2 and based on technical analysis, it seems that there is a possibility to go long. (two different target prices have been found. Fundamental News. Zomedica Pharmaceuticals Corp. Announces $30 Million Public Offering. Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the pricing of its previously announced public offering of 187,500,000 common shares (or common share equivalents) of the Company, together with short-term warrants to purchase up to 187,500,000 common shares, at a combined public offering price of $0.16 per share and accompanying warrant. Each common share (or common share equivalent) is being sold in the offering together with one two-year warrant to purchase one common share at an exercise price of $0.16 per common share. There is no public trading market for the warrants, and Zomedica does not expect a market to develop. Zomedica intends to use the net proceeds from the offering primarily for the continued development of its TRUFORMA™ diagnostic platform, including making milestone payments, as they come due, under its existing license and collaboration agreements, other general corporate and working capital purposes and may use a portion of the net proceeds to repurchase some or all of its outstanding Series 1 Preferred Shares, although no agreement has been reached with respect to the terms or conditions of any such repurchase.
AMEX:ZOMLong
by Mauriello
5
ZOM - Mainly based on Fundamental AnalysisZomedica Pharmaceuticals (NYSEMKT:ZOM) has priced a public offering of ~133.3M common shares, together with warrants to purchase up to same number of common shares, at a combined price of $0.15/share and accompanying warrant, for expected gross proceeds of ~$20M. Two-year warrants have an exercise price of $0.15/share. Net proceeds will be used for the development of TRUFORMA diagnostic platform, including making milestone payments, working capital and other general corporate purposes. Closing date is May 29
AMEX:ZOMLong
by Mauriello
1